ALNY · CUSIP 02043Q107
Alnylam Pharmaceuticals, Inc.
Reported by 1 of 79 curated managers in Q2 2026, in the holdings snapshot last exported 2026-08-24.
- Managers holding
- 1
- Average portfolio weight
- 0.3%
- Combined reported value
- $588.6M
- Research group
- 79
1 of the 79 superinvestors Shameless Cloning tracks reported Alnylam Pharmaceuticals, Inc. (ALNY) in their Q2 2026 13F filings, worth $588.6M combined, at an average 0.3% of their portfolios. The largest positions by portfolio weight belong to Dodge & Cox Funds (0.3%).
Reporting managers
This is a historical 13F snapshot, not a live shareholder register. The count covers all matched managers; dashboard rankings use only those with at least 95% coverage. Reported value is measured at filing quarter-end, not at today's price.
| Manager / SEC filer | % of portfolio | Reported value |
|---|---|---|
| Dodge & Cox FundsDodge & Cox | 0.3% | $588.6M |